Docoh
Loading...

ABMC American Bio Medica

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

Company profile

Ticker
ABMC
Exchange
Website
CEO
Melissa A. Waterhouse
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
141702188

ABMC stock data

(
)

Calendar

31 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 61K 61K 61K 61K 61K 61K
Cash burn (monthly) 54.67K 3.17K 57.33K 42.33K 47K 37.33K
Cash used (since last report) 353.46K 20.47K 370.7K 273.72K 303.89K 241.39K
Cash remaining -292.46K 40.53K -309.7K -212.72K -242.89K -180.39K
Runway (months of cash) -5.3 12.8 -5.4 -5.0 -5.2 -4.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 20 Neff Jean Common Shares Grant Aquire A No No 0.37 35,461 13.12K 66,226
1 Jul 20 Jerome Peter Common Shares Grant Aquire A No No 0.37 35,461 13.12K 80,610
1 Jul 20 Chaim Davis Common Shares Grant Aquire A No No 0.37 35,461 13.12K 240,561
8 Apr 20 Neff Jean Common Shares Grant Aquire A No No 0.21 7,751 1.63K 30,765
8 Apr 20 Jerome Peter Common Shares Grant Aquire A No No 0.21 7,751 1.63K 45,149

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • The drug testing market is highly competitive.
  • Possible inability to hire and retain qualified personnel.
  • Any adverse changes in our regulatory framework could negatively impact our business, and costs to obtain regulatory clearance are material.
  • We rely on intellectual property rights and contractual non-disclosure obligations to protect our proprietary information (including customer information). These rights and obligations may not adequately protect our proprietary information, and an inability to protect our proprietary information can harm our business.
  • One of our customers accounted for more than 10% of our total net sales in Fiscal 2019.
  • We depend on key personnel to manage our business effectively.
  • We rely on third parties for raw materials used in our drug test products and in our bulk test strip contract manufacturing processes.
  • We have a significant amount of raw material and “work in process” inventory on hand that may not be used in the year ended December 31, 2020 if the expected configuration of sales orders is not received at projected levels.
  • Inability to meet our operating plans could have a material adverse effect on our future performance.
  • We incur costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives.
  • Inability to comply with our debt obligations could result in our creditors declaring all amounts owed to them due and payable with immediate effect, or result in the collection of collateral by the creditor; both of which would have an adverse material impact on our business and our ability to continue operations.
  • We have a history of incurring net losses and as of December 31, 2019, we have a negative stockholders’ equity.
  • We may need additional funding for our existing and future operations.
  • Potential issuance and exercise of new options and warrants and, exercise of outstanding options could adversely affect the value of our securities.
  • Substantial resale of restricted securities may depress the market price of our securities.
  • Our securities are currently trading on the OTC Markets Group (under their OTC Pink® Open Market), and are subject to SEC “penny stock,” rules, which could make it more difficult for a broker-dealer to trade our common shares, for an investor to acquire or dispose of our common shares in the secondary market and for us to retain or attract market makers.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: announced, ASC, certified, CLIA, complement, criteria, evidence, flat, formal, great, high, Laboratory, Logix, malaria, order, portfolio, preferred, presumption, range, rebut, rescinding, respiratory, RSV, RT, run, single, Smart, step, tool, turnover, vaccine, wide
Removed: director, expanding, lost